Kyowa Hakko Kogyo Co., Ltd.

Nippon Telegraph and Telephone Corporation

Emory University

Nutriquest, LLC

Kyowa Hakko Bio Co., Ltd.

Kyowa Hakko Kogyo

Furukawa Research Office Co., Ltd.

Satoru Furukawa

Takao Yamashita

Toshihide Nakanishi

Dean P Jones

Hideo Nishimura

Yasuhiko Yoshimura

Masato Ikeda

Tetsuo Nakano

Kuniki Kino

Akio Ozaki

Hideo Kawabe

Kenjiro Shimada

Motokazu Nakayama

Junichi Takano

Thomas R Ziegler

Yukinobu Kotani

Masahiro Sugimoto

Junicho Takano

Mariko Shitashige

Satoshi Odo

Hitoshi Ohori

Takao Mukai

Mitsuyo Matsumoto

Thomas Ziegler

Hideo Kyowa Hakko Kogyo Co Ltd Kawabe

To provide a terminal registration system and a terminal registration method for improving user convenience in registration of a new terminal to a plurality of service sites. The registered terminalincludes an Authenticatorincluding service site list informationthat associates private keys and URLs for access to service sites with each other. A Registration Manageracquires the service site list informationfrom the Authenticatorof the registered terminal. Then, the Registration Managerperforms FIDO authentication for a registration target service site using a private key of the registered terminal, on the basis of the acquired service site list information, and performs Registration of a newly generated cryptographic key at the new terminal

Terminal registration system and terminal registration method

[Problem] To provide a terminal registration system and a terminal registration method for improving user convenience in registration of a new terminal to a plurality of service sites. [Solution] The registered terminalincludes an Authenticatorincluding service site list informationthat associates private keys and URLs for access to service sites with each other. A Registration Manageracquires the service site list informationfrom the Authenticatorof the registered terminalThen, the Registration Managerperforms FIDO authentication for a registration target service site using a private key of the registered terminalon the basis of the acquired service site list informationand performs Registration of a newly generated cryptographic key at the new terminal

The present invention provides an agent that suppresses a decrease in arterial oxygen saturation or increases decreased arterial oxygen saturation, and that can be ingested by a relatively simple method and has excellent immediate effectivity and persistence. The agent of the invention comprises orotic acid or a salt thereof as an active ingredient, which is absorbed into the body via oral mucosa. When the agent is absorbed in the body via oral mucosa it suppresses a decrease in arterial oxygen saturation or increases decreased arterial oxygen saturation. The agent is effective for improvement or prevention of a symptom or disease related to a decrease in arterial oxygen saturation, such as exercise, alcohol drinking, a decrease in oxygen concentration in air, reduced cardiopulmonary function, and respiratory arrest, and a symptom or disease caused by hypoxia, in particular, for prevention of an increase in uric acid level.

Arterial oxygen saturation degree improver

A composition and a method effective in preventing or treating stomatitis are presented. The composition contains glutathione or a pharmaceutically acceptable salt thereof and/or orotic acid or a derivative thereof or a pharmaceutically acceptable salt thereof is provided.

Composition and method for treatment of stomatitis

The invention provides a composition for preventing or treating infectious diseases of a virus belonging to the Coronavirus family or Flavivirus family, the composition containing one or more substances selected from reduced glutathione or oxidized glutathione or pharmaceutically acceptable salts thereof and catechin, and a composition for preventing or treating infectious diseases of a virus belonging to the Coronavirus family or Flavivirus family, the composition containing reduced glutathione or oxidized glutathione or pharmaceutically acceptable salts thereof and catechin.

Preventive or therapeutic composition for viral infectious disease

A temperature-sensitive plasmid which is capable of autonomous replication inK-12 at 10&#x2013;30&#xb0; C., but, at a temperature of 33&#xb0; C. or more, is incapable of autonomous replication inK-12 or is distributed unhomogeneously upon the cell division ofK-12, thereby not to be stably carried within cells ofK-12 under said temperature, and which is incapable of autonomous replication in a microorganism belonging to the genusother thanK-12 or is distributed unhomogeneously upon cell division of said microorganism at any temperature, thereby not to be stably carried within cells of said microorganism.

[object Object]

Administration of one or more of glutathione, its disulfide dimer, ascorbate-2-phosphate, or N-acetyl-L-cysteine, with or without antioxidants, is suitable for the treatment of influenza virus infection, as well as prophylactic prevention of influenza virus infection.

Compounds and their combinations for the treatment of influenza infection

Disclosed is a process for producing L-leucine which comprises culturing in a medium a microorganism belonging to the genus Escherichia and having resistance to a leucine analogue and an ability to produce L-leucine, allowing L-leucine to accumulate in the culture, recovering L-leucine therefrom.

Process for producing L-leucine

Disclosed is a process for producing an L-amino acid which comprises culturing a microorganism belonging to the genus Escherichia, having resistance to 2-ketobutyric acid and ability to produce the L-amino acid in a medium until the L-amino acid is accumulated in the medium, and recovering the L-amino acid therefrom.

Process for producing L-amino acid

Disclosed is a process for producicng L-threonine, which comprises culturing in a medium a microorganism belonging to the genus Escherichia and having a resistance to cysteine or cystine, or their analogue and an ability to produce L-threonine until L-threonine is accumulated in the culture broth, and recovering L-threonine therefrom.

Process for producing L-threonine

A process is disclosed for producing L-threonine, the process involves culturing in a medium a microorganism of the genus Escherichia capable of producing L-threonine which has resistance to at least one of rifampicin, lysine, methionine, aspartic acid and homoserine, or a decreased ability to degrade L-threonine, accumulating L-threonine in the culture liquor and recovering L-threonine therefrom.

A process is disclosed for producing L-threonine, the process involves culturing in a medium a microorganism belonging to the genus Escherichia and having resistance to rifampicin, lysine, methionine, aspartic acid and homoserine, accumulating L-threonine in the culture and recovirng L-threonine therefrom.

Growing community of inventors

Tokyo, Japan

Satoru Furukawa